Nightingale Health: Quick steps forward at the start of the journey
The commercialization of Nightingale’s technology is currently taking place on a broad front. Preventive health care has significant potential, but the commercialization of Nightingale’s technology and the ramping up the business are in their initial stages. If successful the company offers significant potential returns and the story of Nightingale has, in our view, only strengthened since the IPO, which counterbalances the significant risk associated with commercialization. However, the market seems to require much stronger evidence from the company than our expectations, which are hard to provide in the short term in the current development phase.
Nightingale Health
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures16.09.2021
2021 | 22e | 23e | |
---|---|---|---|
Revenue | 2.1 | 2.9 | 8.8 |
growth-% | 31.88 % | 39.36 % | 203.45 % |
EBIT (adj.) | -5.3 | -7.1 | -13.2 |
EBIT-% (adj.) | -253.63 % | -245.37 % | -150.02 % |
EPS (adj.) | -0.13 | -0.13 | -0.23 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |